Cargando…

Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial

BACKGROUND: The standard neoadjuvant treatments in patients with esophageal squamous cell carcinoma (ESCC) still have either poor safety or efficacy. Better therapies are needed in China. METHODS: This was an open-label, single-arm, phase 2 trial. Patients with potentially resectable ESCC (cT1b-3, N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xiaofeng, Xu, Xiang, Wang, Danping, Liu, Jinyuan, Sun, Jing, Lu, Mingjie, Wang, Rui, Hui, Bingqing, Li, Xiaofei, Zhou, Chenchen, Wang, Min, Qiu, Tianzhu, Cui, Shiyun, Sun, Nana, Li, Yang, Wang, Fufeng, Liu, Cuicui, Shao, Yang, Luo, Jinhua, Gu, Yanhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923273/ https://www.ncbi.nlm.nih.gov/pubmed/36759013 http://dx.doi.org/10.1136/jitc-2022-005830

Ejemplares similares

Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer
por: Wei, Wei, et al.
Publicado: (2022)

IMMU-03. UPDATES ON BRAINCHILD-01, -02, AND -03: PHASE 1 LOCOREGIONAL CAR T CELL TRIALS TARGETING HER2, EGFR, AND B7-H3 FOR CHILDREN WITH RECURRENT CNS TUMORS AND DIPG
por: Vitanza, Nicholas, et al.
Publicado: (2020)

Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial
por: Han, Xiao, et al.
Publicado: (2022)

Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients
por: Zhang, Wen, et al.
Publicado: (2022)

Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis
por: Guo, Weinan, et al.
Publicado: (2022)

IMMU-03. CHARACTERIZING THE IMMUNE MICROENVIRONMENT OF PEDIATRIC BRAIN TUMORS
por: Galvin, Robert, et al.
Publicado: (2021)

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
por: Yang, Weixiong, et al.
Publicado: (2022)

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib
por: Yang, Yang, et al.
Publicado: (2020)

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
por: Liu, Jun, et al.
Publicado: (2022)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
por: Chen, Xiaofeng, et al.
Publicado: (2020)

Interferon gamma inhibits CXCL8–CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer
por: Zhang, Mingjie, et al.
Publicado: (2020)

Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis
por: Liu, Nian, et al.
Publicado: (2023)

Identification of an HLA-A*0201–restricted CD8(+) T-cell epitope SSp-1 of SARS-CoV spike protein
por: Wang, Baomei, et al.
Publicado: (2004)

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
por: Shen, Lin, et al.
Publicado: (2020)

Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors
por: Du, Yang, et al.
Publicado: (2022)

Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
por: Massa, Chiara, et al.
Publicado: (2020)

HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
por: Song, Yan, et al.
Publicado: (2020)

High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy
por: Han, Dingpei, et al.
Publicado: (2023)

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma
por: He, Xiran, et al.
Publicado: (2020)

ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
por: Sheng, Hailong, et al.
Publicado: (2020)

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
por: Xia, Yongxiang, et al.
Publicado: (2022)

PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression
por: Zhang, Zhiwei, et al.
Publicado: (2023)

Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study
por: Xia, Lingfang, et al.
Publicado: (2022)

Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells
por: Wang, Sheng, et al.
Publicado: (2023)

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer
por: Abdul Sater, Houssein, et al.
Publicado: (2020)

Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer
por: Sun, Xiaoyan, et al.
Publicado: (2022)

Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth
por: Chen, Xin, et al.
Publicado: (2020)

Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
por: Katz, Matthew H G, et al.
Publicado: (2023)

Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial
por: Hua, Yijun, et al.
Publicado: (2021)

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
por: Liu, Yang, et al.
Publicado: (2021)

Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice
por: Zobel, Michael John, et al.
Publicado: (2020)

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
por: Xie, Lu, et al.
Publicado: (2020)

Intratumor expanded T cell clones can be non-sentinel lymph node derived in breast cancer revealed by single-cell immune profiling
por: Jiao, Shiping, et al.
Publicado: (2022)

Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
por: Ferris, Robert L, et al.
Publicado: (2021)

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
por: Wislez, Marie, et al.
Publicado: (2022)

SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer
por: Zhao, Jun, et al.
Publicado: (2023)

Intratumoral TIGIT(+) CD8(+) T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer
por: Liu, Zhaopei, et al.
Publicado: (2020)

Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma
por: Leidner, Rom, et al.
Publicado: (2021)

MDR1-EXPRESSING CD4(+) T CELLS WITH TH1.17 FEATURES RESIST TO NEOADJUVANT CHEMOTHERAPY AND ARE ASSOCIATED WITH BREAST CANCER CLINICAL RESPONSE
por: Di Roio, Anthony, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vmivcgm28e27tle3tv7rst1bn1